Transcenta Holding (HKSE:06628) Total Liabilities: HK$338.86 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06628 Transcenta Holding Ltd HKSE:06628
40 GF Score
Price HK$0.91
GF Value HK$0.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Transcenta Holding Total Liabilities?

Transcenta Holding HKSE:06628 +7.06% 40 Total Liabilities is HK$338.86 Mil as of Dec. 2025. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Transcenta Holding's Total Liabilities for the quarter that ended in Dec. 2025 was HK$338.86 Mil.

Transcenta Holding's quarterly Total Liabilities declined from Dec. 2024 (HK$479.00 Mil) to Jun. 2025 (HK$422.54 Mil) and declined from Jun. 2025 (HK$422.54 Mil) to Dec. 2025 (HK$338.86 Mil).

Transcenta Holding's annual Total Liabilities declined from Dec. 2023 (HK$728.09 Mil) to Dec. 2024 (HK$479.00 Mil) and declined from Dec. 2024 (HK$479.00 Mil) to Dec. 2025 (HK$338.86 Mil).

Transcenta Holding Total Liabilities Historical Data

* Premium members only.

The historical data trend for Transcenta Holding's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transcenta Holding Total Liabilities Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 709.44 737.75 728.09 479.00 338.86

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 728.09 614.97 479.00 422.54 338.86
HKSE:06628
40GF Score
Transcenta Holding Ltd HKSE:06628
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transcenta Holding Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Transcenta Holding's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=236.869+(19.242+82.752
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=338.86

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1021.686-682.823
=338.86

Transcenta Holding's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=236.869+(19.242+82.752
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=338.86

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1021.686-682.823
=338.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$338.86 Mil mean?
Transcenta Holding (HKSE:06628) has a Total Liabilities of HK$338.86 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Transcenta Holding and its competitors.
Is Transcenta Holding's Total Liabilities too high?
Transcenta Holding's current Total Liabilities is HK$338.86 Mil. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Total Liabilities compare to VRTX and REGN?
Transcenta Holding's Total Liabilities of HK$338.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Transcenta Holding and its competitors. Transcenta Holding's current Total Liabilities is HK$338.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Total Liabilities is HK$338.86 Mil. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Total Liabilities is HK$338.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transcenta Holding (HKSE:06628) Overvalued in 2026?

Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued. The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29. GuruFocus considers Transcenta Holding to be Significantly Overvalued.

Key valuation signals for HKSE:06628:

  • Total Liabilities: HK$338.86 Mil
  • GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transcenta Holding Business Description

Address B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score

Get the complete analysis for HKSE:06628

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.91
Price
HK$0.29
GF Value